Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.

MLA

Julius, U., et al. “Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.” Clinical Research in Cardiology Supplements, vol. 14, no. Suppl 1, Apr. 2019, pp. 45–50. EBSCOhost, https://doi.org/10.1007/s11789-019-00099-z.

APA

Julius, U., Tselmin, S., Schatz, U., Fischer, S., & Bornstein, S. R. (2019). Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clinical Research in Cardiology Supplements, 14(Suppl 1), 45–50. https://doi.org/10.1007/s11789-019-00099-z

Chicago

Julius, U, S Tselmin, U Schatz, S Fischer, and S R Bornstein. 2019. “Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.” Clinical Research in Cardiology Supplements 14 (Suppl 1): 45–50. doi:10.1007/s11789-019-00099-z.